Aptargroup, Inc. (ATR) Stock Price & Analysis
Aptargroup, Inc. (ATR) rose 2.60% to USD 132.36 as of July 25, 2026 at 03:01 UTC, according to Nexqual real-time market data.
ATR last closed at USD 129; the session ranged USD 129.77–132.73 on volume of 250,204 shares. Market capitalization is $8.45B, with a 52-week range of USD 103.23–163.09 (NYQ). Source: Nexqual, July 25, 2026 at 03:01 UTC.
Key Statistics (as of July 25, 2026 at 03:01 UTC)
| Price | USD 132.36 |
|---|---|
| Change | ▲ 2.60% (up) |
| Previous Close | USD 129 |
| Open | USD 129.59 |
| Day Range | USD 129.77 – 132.73 |
| 52-Week Range | USD 103.23 – 163.09 |
| Volume | 250,204 shares |
| Market Cap | $8.45B |
| Exchange | NYQ |
Technical Analysis (ATR)
Nexqual's technical model rates ATR "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:01 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 66.66 (neutral) |
| vs SMA50 | Above (USD 121.12) |
| MACD | 2.59 (positive) |
Analyst Ratings (ATR)
Wall Street analysts rate ATR "Strong Buy" based on 7 analysts, with a mean price target of USD 165.43 (range USD 140–220), per Nexqual as of July 25, 2026 at 03:01 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 165.43 |
| High Target | USD 220 |
| Low Target | USD 140 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (ATR)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.35 |
| Revenue Estimate | $1.01B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.19 vs est 1.15 ▲ beat |
| 2025-12-31 | USD 1.25 vs est 1.23 ▲ beat |
| 2025-09-30 | USD 1.62 vs est 1.57 ▲ beat |
| 2025-06-30 | USD 1.66 vs est 1.59 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:01 UTC.
Financials & Fundamentals (ATR)
| Total Revenue | $3.87B |
|---|---|
| Revenue Growth (YoY) | +10.80% |
| Gross Margin | +36.67% |
| Operating Margin | +11.06% |
| Profit Margin | +9.98% |
| ROE | +14.80% |
| Debt / Equity | 53.72 |
| Current Ratio | 1.66 |
| Total Cash | $229.48M |
| Total Debt | $1.44B |
| Free Cash Flow | $253.02M |
Source: Nexqual, July 25, 2026 at 03:01 UTC.
Financial Health Score (ATR)
Nexqual rates Aptargroup, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:01 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 37%, operating 11% |
| Balance Sheet | Solid — $229M cash vs $1.44B debt |
| Cash Flow | Solid — FCF $253M, 7% margin |
| Efficiency | Mixed — ROE 15%, ROA 6.6% |
Ownership (ATR)
| Insider Ownership | +0.88% |
|---|---|
| Institutional Ownership | +97.21% |
| Shares Outstanding | 63.82M |
| Float | 63.19M |
| Short % of Float | +3.26% |
Source: Nexqual, July 25, 2026 at 03:01 UTC.
Leadership (ATR)
Aptargroup, Inc. is led by Stephan B. Tanda (age 60), President, CEO & Executive Director, per Nexqual as of July 25, 2026 at 03:01 UTC.
| President, CEO & Executive Director | Stephan B. Tanda (age 60) |
|---|---|
| Executive VP & CFO | Vanessa Kanu (age 47) |
| President of Aptar Pharma | Gael Touya (age 55) |
| President of Aptar Beauty | Marc Prieur (age 59) |
| Executive VP of Strategic Group Development & President of Aptar Asia | Xiangwei Gong (age 55) |
Major Backers & Investors (ATR)
Notable institutional backers of Aptargroup, Inc. include State Farm Mutual Automobile Insurance Co, Morgan Stanley, Victory Capital Management Inc., according to Nexqual as of July 25, 2026 at 03:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| State Farm Mutual Automobile Insurance Co | 7.43% |
| Morgan Stanley | 5.29% |
| Victory Capital Management Inc. | 3.79% |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 2.98% |
| Victory Portfolios-Victory Sycamore Established Value Fund | 2.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 18.56% |
| BlackRock | 12.95% |
| State Street | 5.39% |
| Geode Capital | 2.65% |
| Dimensional Fund Advisors | 2.36% |
Source: Nexqual, July 25, 2026 at 03:01 UTC.
From Aptargroup, Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Leveraging our proprietary polymer-based technologies, we enable enhanced mitigation of impurities and degradation, product stability, shelf life, and performance across medical device, drug delivery, and selected food protection applications.
- While we expect that these types of new products will come to market in the future, it is difficult to estimate when, as the rigors of pharmaceutical regulations affect the timing of product introductions by our pharmaceutical customers that use our proprietary drug delivery systems.
- We have developed a multi-dose dispensing device suitable for ophthalmic formulations.
- Although Europe represents the largest region for us in terms of sales, our beauty and pharmaceutical customers often export their finished products using our technology around the world for consumption.
Partnerships
- Historically, the environmental impact of these processes has been minimal, and we collaborate with local permitting authorities to ensure we operate responsibly.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLGN | Silgan Holdings Inc. | USD 46.43 | ▲ 1.98% |
| DCI | Donaldson Company, Inc. | USD 92.79 | ▲ 2.01% |
| CSL | Carlisle Companies Incorporated | USD 336.04 | ▲ 2.52% |
| SON | Sonoco Products Company | USD 58.23 | ▲ 5.58% |
| BRC | Brady Corporation | USD 94.5 | ▲ 1.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:01 UTC. This page is informational and not investment advice.